Additionally, Zhang et al. observed that FAT1 mutations were linked to preferable ICI efficacy and immunogenicity in 109 NSCLC patients and validated these connections in 631 melanoma and 1661 pan-cancer patients [6]. This evidence concerns the gene FAT1 and non-small cell lung carcinoma.